Search This Blog

Friday, December 6, 2019

FDA OKs Amgen’s Remicade biosimilar

The FDA approves Amgen’s (AMGN +0.1%) Avsola (infliximab-axxq), its biosimilar to Johnson & Johnson’s (JNJ +0.9%) autoimmune disease med Remicade.
The TNF inhibitor accounted for over 10% of J&J’s Q3 drug sales.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)